Guardant Health Inc (NASDAQ:GH) Expected to Post Quarterly Sales of $46.15 Million

Brokerages expect Guardant Health Inc (NASDAQ:GH) to report $46.15 million in sales for the current quarter, Zacks reports. Four analysts have issued estimates for Guardant Health’s earnings. The highest sales estimate is $47.80 million and the lowest is $44.90 million. Guardant Health posted sales of $21.69 million in the same quarter last year, which suggests a positive year over year growth rate of 112.8%. The firm is expected to announce its next earnings results on Monday, November 18th.

According to Zacks, analysts expect that Guardant Health will report full year sales of $185.95 million for the current year, with estimates ranging from $185.00 million to $187.70 million. For the next financial year, analysts anticipate that the firm will report sales of $256.21 million, with estimates ranging from $247.50 million to $267.60 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that that provide coverage for Guardant Health.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.21. The business had revenue of $53.98 million for the quarter, compared to analysts’ expectations of $35.97 million. Guardant Health had a negative net margin of 60.08% and a negative return on equity of 22.93%. The business’s revenue was up 178.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.75) earnings per share.

Several research analysts have recently issued reports on GH shares. JPMorgan Chase & Co. upped their target price on shares of Guardant Health from $90.00 to $135.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Canaccord Genuity reiterated a “buy” rating and issued a $125.00 target price (up previously from $96.00) on shares of Guardant Health in a research note on Wednesday, August 7th. Cowen set a $110.00 target price on shares of Guardant Health and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Finally, Zacks Investment Research downgraded shares of Guardant Health from a “strong-buy” rating to a “hold” rating in a research note on Saturday, August 10th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Guardant Health currently has an average rating of “Buy” and an average target price of $111.80.

GH traded down $1.37 during midday trading on Friday, reaching $73.36. The company’s stock had a trading volume of 908,372 shares, compared to its average volume of 1,083,396. The stock’s 50-day moving average is $91.61 and its 200-day moving average is $82.51. The firm has a market capitalization of $6.95 billion and a price-to-earnings ratio of -26.20. Guardant Health has a 1 year low of $27.04 and a 1 year high of $112.21.

In related news, Director Stanley J. Meresman sold 10,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $76.36, for a total transaction of $763,600.00. Also, Chairman Amirali Talasaz sold 100,000 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $100.17, for a total transaction of $10,017,000.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,914,867 shares of company stock worth $478,546,806. Insiders own 13.00% of the company’s stock.

A number of institutional investors have recently modified their holdings of GH. Morgan Stanley lifted its position in Guardant Health by 151.8% during the second quarter. Morgan Stanley now owns 4,814,366 shares of the company’s stock valued at $415,624,000 after purchasing an additional 2,902,471 shares during the period. Jennison Associates LLC lifted its position in Guardant Health by 301.7% during the second quarter. Jennison Associates LLC now owns 2,753,535 shares of the company’s stock valued at $237,713,000 after purchasing an additional 2,068,098 shares during the period. Vanguard Group Inc. lifted its position in Guardant Health by 151.1% during the second quarter. Vanguard Group Inc. now owns 2,893,820 shares of the company’s stock valued at $249,824,000 after purchasing an additional 1,741,472 shares during the period. Nuveen Asset Management LLC bought a new position in Guardant Health during the second quarter valued at approximately $106,503,000. Finally, Coatue Management LLC bought a new position in Guardant Health during the second quarter valued at approximately $103,251,000. Institutional investors own 81.40% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.

Recommended Story: Cost of Goods Sold (COGS)

Get a free copy of the Zacks research report on Guardant Health (GH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.